Actively Recruiting
Randomized Trial of Higher Dose Radiation Versus Standard Care in Locally Advanced Unresectable Pancreatic Cancer
Led by NRG Oncology · Updated on 2026-08-25
356
Participants Needed
333
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating dose-escalated radiation therapy compared to usual care in patients with locally advanced unresectable pancreatic ductal adenocarcinoma who have already received 4 to 8 months of chemotherapy. The study aims to determine if this higher-dose radiation can improve 3-year overall survival compared to standard therapies such as continued chemotherapy, observation, or standard radiation. The trial also assesses progression, chemotherapy-free intervals, toxicity, and quality of life measures. Participants are randomly assigned to either standard care, which includes options like continued chemotherapy regimens FOLFIRINOX, NALIRIFOX, or gemcitabinenab-paclitaxel, standard radiation therapy with concurrent chemotherapy, or observation, or to dose-escalated radiation therapy delivered in either a 5-fraction or 25-fraction regimen with or without concurrent chemotherapy. Blood samples, CT scans, MRI, and tumor biopsies are collected throughout the study. Optional PETCT scans may be performed before treatment. Participants are followed with regular assessments every 3 months for 2 years, then annually for 3 more years. Researchers monitor overall survival, local tumor progression, progression-free survival, chemotherapy-free intervals, adverse events, and quality of life using standardized questionnaires. Biospecimens are also collected for future analysis. The total study duration spans up to 5 years of follow-up after randomization.
CONDITIONS
Brief Title
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here